

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

ANNOUNCEMENT OF TURNOVER AND GROSS PROFIT INFORMATION FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2012

The Company announces the turnover and gross profit information, which has not been reviewed by its auditors, for the nine months ended 30 September 2012.

The board of directors (the “Board”) of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “Company”) announces the financial information of turnover and gross profit of the Company and its subsidiaries (together, the “Group”) for the nine months ended 30 September 2012 based on its management accounts which have not been reviewed by the auditors.

Turnover of the Group, which has not been reviewed by the auditors, for the nine months ended 30 September 2012 increased by 16.1% as compared with the same period of 2011 to HK\$1,776 million, with gross profit margin of 42.8% (for the nine months ended 30 September 2011: 43.0%) and in particular:

- Turnover of **intravenous infusion solution** for the first nine months in 2012 increased by approximately 35.5% as compared with the same period of 2011 to HK\$1,015 million, with gross profit margin of 43.5% (for the nine months ended 30 September 2011: 42.8%). Among which, sales of Non-PVC Soft Bag infusion solution was HK\$418 million, representing 44.8% of the total sales of intravenous infusion solution and an increase of 59.7% as compared with the same period of 2011; sales of PP Plastic Bottle infusion solution was HK\$342 million, representing 36.7% of the total sales of intravenous infusion solution and an increase of 19.0% as compared with the same period of 2011; and

- Turnover of **antibiotics finished medicines and non-antibiotics finished medicines** businesses for the first nine months in 2012 decreased by approximately 9.5% to HK\$392 million and increased by approximately 6.4% to HK\$369 million respectively as compared with the same period of 2011, with the gross profit margin of 41.9% (for the nine months ended 30 September 2011: 43.1%); among which, sales of Lijunsha amounted to HK\$215 million, represented a decrease of 7.7% as compared with the same period of 2011; sales of Paiqi amounted to HK\$97.06 million, represented an increase of 7.8% as compared with the same period of 2011; sales of Dobesilate amounted to HK\$57.86 million, represented an increase of 1.1% as compared with the same period of 2011; sales of Lixiding amounted to HK\$26.38 million, represented an increase of 8.5% as compared with the same period of 2011.

In terms of business segments analysis, intravenous infusion solution, antibiotics finished medicines and non-antibiotics finished medicines accounted for approximately 57.1%, 22.1% and 20.8% respectively of the total turnover of the Group, which has not been reviewed by the auditors, for the first nine months in 2012 (for the nine months ended 30 September 2011: 49.0%, 28.3% and 22.7% respectively).

Shareholders and investors are advised to exercise caution in dealing in the shares of the Company.

On behalf of the Board
Chow Hing Yeung
Company Secretary

Hong Kong, 16 October 2012

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Xie Yunfeng, Mr. Huang Chao, Mr. Wang Xianjun, Mr. Duan Wei, Mr. Bao Leyuan and Ms. Gao Shuping as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.